NewEdge Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.66M | Sell |
17,146
-189
| -1% | -$88.1K | 0.03% | 533 |
|
|
2025
Q4 | $7.86M | Buy |
17,335
+5,617
| +48% | +$2.42M | 0.03% | 512 |
|
|
2025
Q3 | $4.59M | Sell |
11,718
-211
| -2% | -$88.2K | 0.02% | 664 |
|
|
2025
Q2 | $5.31M | Buy |
11,929
+986
| +9% | +$454K | 0.03% | 548 |
|
|
2025
Q1 | $5.31M | Sell |
10,943
-1,708
| -14% | -$796K | 0.03% | 486 |
|
|
2024
Q4 | $5.09M | Buy |
12,651
+1,294
| +11% | +$600K | 0.03% | 493 |
|
|
2024
Q3 | $5.28M | Sell |
11,357
-2,275
| -17% | -$1.09M | 0.03% | 453 |
|
|
2024
Q2 | $6.39M | Buy |
13,632
+709
| +5% | +$308K | 0.05% | 370 |
|
|
2024
Q1 | $5.4M | Buy |
12,923
+2,619
| +25% | +$1.11M | 0.05% | 370 |
|
|
2023
Q4 | $4.41M | Buy |
10,304
+650
| +7% | +$240K | 0.04% | 393 |
|
|
2023
Q3 | $3.36M | Buy |
9,654
+1,128
| +13% | +$395K | 0.04% | 421 |
|
|
2023
Q2 | $3M | Buy |
8,526
+3,034
| +55% | +$1.02M | 0.03% | 456 |
|
|
2023
Q1 | $1.76M | Sell |
5,492
-262
| -5% | -$78.6K | 0.02% | 579 |
|
|
2022
Q4 | $1.47M | Sell |
5,754
-275
| -5% | -$83.8K | 0.04% | 401 |
|
|
2022
Q3 | $1.75M | Buy |
6,029
+1,354
| +29% | +$390K | 0.03% | 465 |
|
|
2022
Q2 | $1.32M | Buy |
+4,675
| New | +$1.25M | 0.02% | 566 |
|
|
2022
Q1 | – | Sell |
-3,863
| Closed | -$848K | – | 1644 |
|
|
2021
Q4 | $848K | Buy |
3,863
+2,276
| +143% | +$443K | 0.01% | 819 |
|
|
2021
Q3 | $288K | Sell |
1,587
-305
| -16% | -$59.5K | 0.01% | 915 |
|
|
2021
Q2 | $381K | Buy |
1,892
+534
| +39% | +$112K | 0.01% | 815 |
|
|
2021
Q1 | $292K | Sell |
1,358
-931
| -41% | -$204K | 0.01% | 822 |
|
|
2020
Q4 | $541K | Sell |
2,289
-13,367
| -85% | -$3.07M | 0.02% | 600 |
|
|
2020
Q3 | $4.26M | Buy |
15,656
+12,370
| +376% | +$3.41M | 0.15% | 145 |
|
|
2020
Q2 | $954K | Buy |
3,286
+1,520
| +86% | +$412K | 0.04% | 370 |
|
|
2020
Q1 | $420K | Buy |
1,766
+794
| +82% | +$182K | 0.02% | 503 |
|
|
2019
Q4 | $212K | Buy |
+972
| New | +$197K | 0.01% | 750 |
|
|
2019
Q2 | – | Sell |
-1,280
| Closed | -$235K | – | 705 |
|
|
2019
Q1 | $235K | Buy |
1,280
+30
| +2% | +$5.54K | 0.02% | 592 |
|
|
2018
Q4 | $207 | Buy |
+1,250
| New | +$217K | 0.01% | 577 |
|
|
2017
Q3 | – | Sell |
-111
| Closed | -$14.3K | – | 1108 |
|
|
2017
Q2 | $14.3K | Buy |
+111
| New | +$13.4K | ﹤0.01% | 836 |
|
Other funds holding VRTX
VCM
VPM
NewEdge Advisors's VRTX Position: Q1 2026 in Review
NewEdge Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 1.1% in Q1 2026, selling an estimated $88.1K and leaving 17,146 shares worth $7.66M. The position accounts for 0.03% of the portfolio, ranked #533.
NewEdge Advisors first reported a position in VRTX in Q2 2017 and has held it in 28 quarters since. The position peaked at $7.86M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- NewEdge Advisors held 17,146 shares of Vertex Pharmaceuticals worth $7.66M as of Q1 2026.
- NewEdge Advisors sold 189 Vertex Pharmaceuticals shares in Q1 2026, an estimated $88.1K.
- Vertex Pharmaceuticals made up 0.03% of NewEdge Advisors's portfolio in Q1 2026, its #533 holding.
- NewEdge Advisors first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 28 quarters since.
- NewEdge Advisors's Vertex Pharmaceuticals position peaked at $7.86M in Q4 2025.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.